Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ca82d85ba526a9d85bc53f9c7a5be440 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2800-80 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-62 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-11 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y305-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-102 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-907 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-78 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-22 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-62 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-11 |
filingDate |
2019-02-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_df68f90cd2fc68d7650ddc831600a844 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_619e1ed8f13b81b6bc2f218247c69c6c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4fb3521388df3b2777f39f9949376a93 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_81614ac6707dddf9c502c0b4868de9f2 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_089847b8424e9781c2f87078426eb43e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_201bb78e16c5db3d317db65488d344dc |
publicationDate |
2020-12-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
EP-3755726-A1 |
titleOfInvention |
Fusion proteins for base editing |
abstract |
Provided are fusion proteins that include an apolipoprotein B mRNA editing enzyme catalytic subunit 3A (APOBEC3A) and a clustered regularly interspaced short palindromic repeats (CRISPR) -associated (Cas) protein, optionally further with uracil glycosylase inhibitor (UGI). Such a fusion protein is able to conduct base editing in DNA by deaminating cytosine to uracil, even when the cytosine is in a GpC context or is methylated. |
priorityDate |
2018-02-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |